CRISPR Therapeutics AG (LON:0VRQ)

Market Cap	3.74B +46.5%
Revenue (ttm)	3.11M -89.1%
Net Income	-430.55M
EPS	-4.66
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,679
Open	54.60
Previous Close	55.12
Day's Range	51.88 - 54.75
52-Week Range	36.20 - 78.47
Beta	1.74
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 3, 2026

About CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as deve...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 393
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0VRQ

Financial Performance

In 2025, CRISPR Therapeutics AG's revenue was $3.51 million, a decrease of -90.59% compared to the previous year's $37.31 million. Losses were -$581.60 million, 58.8% more than in 2024.

Financial numbers in USD